Exciting Therapeutic Advances of 2009 to Highlight Eleventh Annual BIO CEO & Investor Conference
“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts in 2009, from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO. “This conference provides the opportunity for industry executives and members of the investment community to meet, network, and address the challenges and solutions needed for the current market environment.”
The BIO CEO & Investor Conference’s therapeutic workshops will focus on topics addressing the latest developments in therapies for a wide range of diseases. This year’s therapeutic workshop topics include:
Metabolic: Feeding the Need for New Treatments in Obesity
Monday, February 9, 11am-12:10pm
Moderator: Liana Moussatos, PhD, Senior Healthcare Research Analyst, Wedbush
Pacific Growth Life Sciences
Industry: Arena Pharmaceuticals, Inc.
Vivus , Inc.
Clinician: F. Xavier Pi-Sunyer, MD, MPH,Professor of Medicine at Columbia
University College of Physicians and Surgeons and Professor of Applied
Physiology at Columbia Teachers College
Nephrology: The Future of Anemia Management—Up-and-Coming Products to Stimulate an Anemic Market
Monday, February 9, 12:30-1:35pm
Moderator: Eric Schmidt, Ph.D, Managing Director, Cowen & Company, LLC
Industry: Affymax , Inc.
AMAG Pharmaceuticals, Inc.
Clinician: Steven Fishbane, MD, Professor of Medicine at the State University of
New York at Stony Brook School of Medicine
Chaim Charytan, MD, Chief of the Renal Division at New York Hospital
Medical Center of Queens
Infectious Disease: Reinforcements on the Way—A Surge of New Treatments to Combat HCV
Monday, February 9, 1:45-2:55pm
Moderator: Jason Kolbert, Managing Director, Research, ThinkEquity LLC
Industry: Anadys Pharmaceuticals, Inc.
Human Genome Sciences, Inc.
Clinician: Douglas T. Dieterich, MD,Professor of Medicine, Director of
Outpatient Hepatology in the Division of Liver Diseases, and Director of
CME in the Department of Medicine at Mount Sinai School of Medicine
in New York, NY
Human Genetics: Unmet Needs are in the Genes— Treatments for Rare Genetic Disorders
Tuesday, Feb 10, 9:30-10:55am
Moderator: Geoff Porges, Senior Biotechnology Analyst, Sanford C. Bernstein & Co.,
LLC
Industry: Shire Human Genetic Therapies, Inc.
Clinician: Barbara Burton, Director, PKU Program; Professor of Pediatrics,
Northwestern University's Feinberg School of Medicine
Chet Whitley, Professor, Gene Therapy Center, University of Minnesota
Autoimmune: Is the Jury Still Out on Gout?
Tuesday, February 10, 12:30-1:40pm
Moderator: Kimberly Lee, D.O., Senior Healthcare Research Analyst, Wedbush
Pacific Growth Life Sciences
Industry: Ardea Biosciences, Inc.
Regeneron Pharmaceuticals, Inc.
Clinician: Michael Becker, MD, Professor of Medicine in the Section of
Rheumatology in the Department of Medicine, University of Chicago
School of Medicine
Oncology: The Forecast for the Melanoma Market—Partly Sunny or Mostly Cloudy?
Tuesday, February 10, 12:30-1:35pm
Moderator: Mike King, Head of Healthcare & Senior Managing Director
Rodman & Renshaw, LLC
Industry: Medarex , Inc.
Synta Pharmaceuticals Corp.
Clinician: Gary K. Schwartz, MD, Chief, Melanoma and Sarcoma Service at
Memorial Sloan Kettering Cancer Center
Anna C. Pavlick, Assistant Professor of Medicine and Dermatology, NYU
School of Medicine
Neurology: Not in Vein—New Advances in Orally Available Treatments for MS
Tuesday, February 10, 1:45pm-2:55pm
Moderator: Mark Schoenbaum, MD, Managing Director-Senior Analyst
Biotechnology, Deutsche Bank Securities, Inc.
Clinician: Mark J. Tullman, M.D., Director of the Multiple Sclerosis Clinical Care
and Research Center at Columbia University Medical Center in New York
City
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org/. Registration is complimentary for qualified investors and credentialed members of the media.
Advance media registration is now available at https://www.compusystems.com/servlet/ar?evt_uid=746&site=MEDIA.
The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. The meeting attracts institutional investors, industry analysts, and senior biotechnology executives. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and mature biotechnology companies.
Upcoming BIO Events
BIO CEO & Investor Conference 2009
February 9-10, 2009
New York, New York
BIO-Europe Spring
March 16-18, 2009
Milan, Italy
BIO IP Counsels' Committee Conference
March 25–27, 2009
Phoenix, AZ
BIO National Venture Conference
March 31–April 1,2009
Boston, MA
BIO Windhover 2009
April 13-15, 2009
New York, New York
BIO-LES Business Development Basics Course
May 15–17, 2009
Atlanta, GA
May 15–17, 2009
Atlanta, GA
BIO Executive Presentation Workshop
May 17, 2009
Atlanta, GA
2009 BIO International Convention
May 18-21, 2009
Atlanta, Ga.
BioEquity Europe
June 9-10, 2009
Munich, Germany
World Congress on Industrial Biotechnology & Bioprocessing
July 19-22, 2009
Montreal, Quebec, Canada
About BIO
###